neuroClues Raises €10M Series A To Scale AI‑Powered Neurological Biomarkers Across Europe

The round was led by Teampact Ventures, White Fund, and the EIC Fund, with participation from existing investors including InvestBW, Leansquare, and Wallonie Entreprendre, as well as support from Olivier Legrain, CEO of IBA.

Founded in 2020 by Antoine Pouppez, Pierre Daye and Pierre Pouget neuroClues is a MedTech startup developing a compact, non-invasive medical device that analyses eye movements to detect neurological disorders. Its CE-marked system uses AI to generate objective biomarkers helping clinicians diagnose and monitor conditions earlier and more accurately.

The company highlights the growing challenge of neurodegenerative diseases which affect 1 in 3 people and are often misdiagnosed. Current diagnostic methods rely heavily on subjective observation or expensive imaging, which may not detect early stage issues.

Read Also - Trent AI Raises $13Million Seed Funding To Secure AI Agents

neuroClues addresses this gap with a portable device that captures high speed infrared eye data during simple tasks. Its AI then converts this data into reliable biomarkers, enabling faster, more accurate and accessible neurological diagnosis.

As neuroClues collects large-scale clinical data, its platform becomes smarter, helping identify specific conditions such as distinguishing Parkinson’s from similar disorders, detecting early signs of Alzheimer’s, and identifying concussion-related issues.

The company received CE certification in January 2025 and has already deployed over 30 devices across several European countries, including France, Belgium, Germany and the UK, in hospitals, clinics, and research centres. It is also seeing growing interest from clinicians.

This traction is supported by key milestones, including integration into the Paris Brain Institute’s research programs and participation in a large 25,000-patient study to build a major database of eye-movement biomarkers.

neuroClues was also selected for Bpifrance’s National Prevention Accelerator and joined a French presidential delegation to India to build global partnerships.

To support growth, the company has appointed Bart Stulens as Chief Commercial Officer and is expanding its team across Europe. It has also opened a €1.5 million investment opportunity on LITA, allowing individual investors to participate.

“This Series A validates our technology and our ability to execute. CE certification in five months. First commercial deployments within weeks. A normative database project with 25,000 participants. Today, we give clinicians an objective way to assess neurological anomalies. As our dataset grows, our solution will help them identify specific pathologies earlier and more precisely than ever before. That is where we are headed,” said Antoine Pouppez, CEO, neuroClues.